Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 20, 2025

Elucidating the Pharmacological Basis of Xianling Cifang Granules Against Breast Cancer. A Metabolomic Profiling Study.

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYang WangRYRui YangYSYouyang Shi

Discussion

Loading...

Member takes

Overview

Metabolomic profiling reveals anti-breast cancer mechanisms of XLCF, highlighting network pharmacology and molecular docking interactions.

Key Points

  • XLCF treatment significantly affected 62 serum metabolites, indicating metabolic reprogramming related to breast cancer.
  • The study identifies 122 prototype constituents entering circulation, with icaritin highlighted for its anti-breast cancer activity.
  • Network pharmacology predicted key therapeutic targets including ADORA1 and AKR1B1, validated through molecular docking.
  • The findings support the use of XLCF in clinical settings, emphasizing the integration of metabolomics in Traditional Chinese Medicine research.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68d43a00713b0b5dfea7a2a1https://doi.org/10.2147/dddt.s530516
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mechanisms of Actinidia chinensis Planch roots in the treatment of breast cancer based on network pharmacology and molecular docking2025
  2. 2Network pharmacology analysis and clinical efficacy study of Fuzi Lizhong Decoction combined with XELOX plus sintilimab in the treatment of advanced gastric cancer2025
  3. 3Elucidating Pingxiao Capsules Anti-Breast Cancer Mechanism via Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations2025
  4. 4Exploring the mechanism of Kanglixin capsules in the treatment of non-small cell lung cancer based on network pharmacology and molecular docking2025
  5. 5Unlocking the Anti-Breast Cancer Potential of Aralia chinensis L.2025